This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Long-Acting Injectable Risperidone for Control of Agitation in Dementia

Mehmet Yumru, MD; Murat Eren Özen, MD; Haluk A. Savas, MD; and Salih Selek, MD

Published: October 16, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: There are now many studies showing the effectiveness of risperidone in controlling agitation in patients with dementia, and it has a relatively benign adverse effect profile. Atypical antipsychotic agents are moderately effective in the treatment of behavioral symptoms in patients with dementia.1 Failure to adhere to a prescribed medication regimen by patients with psychosis is one of the most frustrating problems faced by mental health care providers, because of the high risk of relapse associated with that situation.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: